India to Lebanon: Adalimumab Export Trade Route

To import Adalimumab formulations into Lebanon, the following approvals and registrations are necessary:

• Product Registration: An application must be submitted to the National DRA for the registration of the Adalimumab product.

• Dossier Format: The application should be compiled in the Common Technical Document (CTD) format, encompassing:
• Module 1: Administrative information, including cover letter, application form, proposed summary of product characteristics, labeling, and package insert leaflet.
• Module 2: Quality overall summary, pre-clinical and clinical overviews.
• Module 3: Quality, detailing information on the active substance and finished product.
• Module 4: Non-clinical study reports.
• Module 5: Clinical study reports.

• Timelines for Approval: The approval process duration can vary based on the completeness of the submitted dossier and the National DRA's review workload.

• Product Registration Fees: Specific fees are associated with the registration process; applicants should consult the National DRA for the current fee structure.

• GMP Inspection Requirements: The National DRA mandates Good Manufacturing Practice (GMP) compliance for manufacturing facilities. Indian manufacturers exporting to Lebanon must provide a valid GMP certificate issued by the competent authority in India. The National DRA may also conduct its own inspections or require inspection reports from recognized international regulatory bodies.

Indian exporters of Adalimumab formulations to Lebanon must adhere to stringent GMP standards:

• GMP Certifications: Manufacturing facilities must possess a valid GMP certificate issued by the Indian regulatory authority. Additionally, certifications from international bodies such as the World Health Organization (WHO) or the U.S. Food and Drug Administration (USFDA) can enhance credibility.

• Approved Indian Facilities: Specific information regarding Indian facilities currently approved by the National DRA for Adalimumab exports to Lebanon is not publicly disclosed. Exporters should ensure their facilities meet all regulatory requirements and maintain open communication with the National DRA.

• Recent Inspections and Regulatory Actions: While detailed records of National DRA inspections of Indian pharmaceutical companies are not publicly available, Indian manufacturers have faced increased scrutiny from international regulatory bodies. For instance, in 2025, the USFDA conducted 212 inspections of Indian drug facilities, resulting in 11 Official Action Indicated (OAI) classifications, a decrease from 20 in 2024. This trend indicates an improvement in compliance but underscores the necessity for continuous adherence to GMP standards.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports:

• Enhanced GMP Compliance: In December 2023, the Ministry of Health and Family Welfare (MoHFW) in India revised Schedule M of the Drugs Rules to align more closely with WHO-GMP standards. This amendment mandates stronger quality controls across manufacturing processes to enhance drug safety and prevent adulteration. Indian manufacturers exporting to Lebanon must ensure compliance with these updated standards.

• Regulatory Actions: Between February 2024 and February 2025, Indian regulatory authorities canceled licenses of 64 pharmaceutical companies and shut down 17 drug testing laboratories due to non-compliance with GMP standards. These actions highlight the Indian government's commitment to enforcing quality standards, which is crucial for maintaining export eligibility to markets like Lebanon.

• International Inspections: In January 2026, China's National Medical Products Administration (NMPA) suspended imports of certain APIs from Indian manufacturers due to GMP violations. Although this action pertained to APIs, it underscores the importance of stringent GMP compliance for all pharmaceutical products, including finished formulations like Adalimumab.

Indian exporters must stay informed about these developments and ensure their manufacturing practices align with both Indian and international regulatory standards to facilitate uninterrupted exports to Lebanon.

In 2024, Lebanon imported pharmaceutical products totaling $737 million, with the United States accounting for $87 million of this figure. Local production comprises approximately 30% of the pharmaceutical market, primarily through manufacturing drugs under license for international companies.

Adalimumab, a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease, is in demand due to the prevalence of these conditions in Lebanon. The country's aging population and increased healthcare spending contribute to the growing need for such biologic therapies. However, Lebanon's ongoing economic crisis has led to shortages of critical medications, including biologics like Adalimumab, as the Central Bank reduced subsidies for pharmaceutical imports.

Pharmaceutical products under HS code 30021500, including Adalimumab formulations, are exempt from import duties in Lebanon. This exemption aims to ensure the availability of essential medications. There is no Free Trade Agreement (FTA) between India and Lebanon that affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on pharmaceutical imports from India.

In 2024, Lebanon's pharmaceutical imports totaled $737 million, with the United States being the largest supplier, accounting for 11.8% of the total imports. Germany (11.66%), France (8.95%), and Switzerland (7.19%) were also significant suppliers.

India's share of Lebanon's total Adalimumab imports is relatively modest. In 2024, India exported $1.2 million worth of Adalimumab formulations globally, with $0.1 million directed to Lebanon, representing 5% of India's total Adalimumab formulation exports.

Indian manufacturers, such as Reliance Life Sciences Private Limited, are known for offering competitive pricing compared to European and American counterparts. This cost advantage positions Indian suppliers favorably in markets like Lebanon, especially amid economic challenges that heighten the demand for affordable medications.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2025. The country boasts a robust infrastructure for manufacturing finished pharmaceutical formulations, including those containing Adalimumab. In the fiscal year 2024, India registered 134 facilities with the U.S. Food and Drug Administration (FDA) for finished dosage forms, underscoring its compliance with international quality standards. Additionally, numerous Indian manufacturing plants hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP), further attesting to their adherence to stringent quality protocols. The combination of large-scale production capabilities and cost-effective manufacturing processes enables India to offer Adalimumab formulations at competitive prices without compromising on quality.

When comparing Adalimumab formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers leverage economies of scale and efficient production methods to offer Adalimumab formulations at lower prices compared to their EU counterparts. Chinese manufacturers also provide cost-effective options; however, the price advantage is often offset by concerns regarding quality consistency.

• Quality Perception: Indian pharmaceutical companies have established a strong reputation for producing high-quality generic formulations, supported by numerous FDA and WHO-GMP certifications. EU manufacturers are renowned for their stringent quality controls, but their products come at a premium price. Chinese manufacturers have made significant strides in improving quality; however, some markets remain cautious due to past inconsistencies.

• Regulatory Acceptance in Lebanon: Lebanon's Ministry of Public Health recognizes and accepts pharmaceutical products from manufacturers with WHO-GMP and FDA approvals. Indian manufacturers, with their extensive portfolio of such certifications, are well-positioned to meet Lebanon's regulatory requirements.

• Supply Reliability Track Record: Indian pharmaceutical companies have demonstrated a consistent ability to fulfill international orders promptly, supported by a well-established logistics network. EU manufacturers also maintain reliable supply chains but at higher costs. Chinese manufacturers are improving in this area, though some buyers express concerns about potential delays and supply chain disruptions.

The India-Lebanon supply chain for Adalimumab formulations is characterized by reliability and capacity:

• Manufacturing Capacity: India's pharmaceutical sector includes numerous facilities dedicated to producing finished dosage forms, including Adalimumab injections. These facilities are equipped with advanced technologies to meet large-scale production demands.

• Packaging and Cold Chain Capabilities: Indian manufacturers have invested in state-of-the-art packaging solutions and cold chain logistics to ensure the stability and efficacy of temperature-sensitive products like Adalimumab.

• Regulatory Compliance Track Record: Indian pharmaceutical companies have a strong history of adhering to international regulatory standards, with many facilities holding FDA and WHO-GMP certifications. This compliance ensures consistent product quality and safety.

• Capacity Constraints or Expansion Plans: As of 2025, leading Indian manufacturers have announced plans to expand their production capacities to meet growing global demand for biosimilars, including Adalimumab formulations. These expansions aim to enhance supply reliability and reduce lead times for international buyers.

For Lebanese buyers seeking to source Adalimumab formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Adalimumab formulations.

• Minimum Order Quantities (MOQs): Indian manufacturers typically require MOQs to optimize production efficiency. Buyers should negotiate MOQs that align with their demand forecasts to balance inventory levels and cost-effectiveness.

• Payment Terms: Common payment terms in India-Lebanon pharmaceutical trade include letters of credit (LC) and advance payments. Buyers should establish clear payment agreements to facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers comply with Lebanon's Ministry of Public Health regulations and can provide the necessary documentation for product registration and importation.

By implementing these strategies, Lebanese buyers can establish a reliable and cost-effective supply chain for Adalimumab formulations sourced from India.

By adhering to these guidelines, Lebanese companies can effectively qualify Indian suppliers of Adalimumab formulations, ensuring compliance with regulatory requirements and the delivery of high-quality pharmaceutical products.